TCA Cellular Therapy (101 E. Fairway Drive, Suite 514, Covington, 985-867-4860; www.tcacellulartherapy.com), among the top 10 companies in the U.S. researching stem cell therapies, has received a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. Department of Health and Human Services. TCA will use the grant to continue developing adult stem cell therapies for heart attack, Lou Gehrig's Disease, spinal cord injury and a lack of blood flow to the legs or heart. The QTDP grant, part of the Patient Protection and Affordable Care Act of 2010, provides a 50 percent tax credit for investments in qualifying projects.
The FDA this year allowed TCA to conduct the only adult stem cell clinical trial in the U.S. for the treatment of Lou Gehrig's disease. — Kandace Power Graves